varegacestat
varegacestat: developed by 1 company · 3 clinical trials tracked.
varegacestat evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
How could varegacestat → IMNM affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Immunome Inc. (IMNM) | Phase 1 |
Clinical Trials (3)
A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Varegacestat in Participants With or Without Hepatic Impairment
Primary endpoint: PK of varegacestat and metabolite from a single oral dose of varegacestat in hepatic impaired adult participants to matched healthy adult participants.
A Phase 1, Open-Label Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of [14C]Varegacestat Following a Single Oral Dose in Healthy Adult Male Participants
Primary endpoint: The mass balance of varegacestat following administration of a single oral dose (containing ~100 µCi) [14C]varegacestat in healthy adult male participants.
A Phase 1, Randomized, Single-Dose, Positive- and Placebo-Controlled, 3-Way Crossover Study to Evaluate the Effects of Varegacestat on Cardiac Repolarization in Healthy Participants
Primary endpoint: Placebo-corrected change from baseline QTc and varegacestat and its metabolite, AL102 MTB, plasma concentrations
Frequently asked questions
Who is developing varegacestat?
varegacestat is being developed by Immunome Inc..
How many clinical trials involve varegacestat?
BioSniper tracks 3 clinical trials involving varegacestat.